Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide for Refractory Uremic Pruritus
NCT05525234Phase 4Unknown
- Sponsor
- Renji Hospital
- Start
- Sep 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, double-blind trial in uremic pruritus comparing Thalidomide group with Placebo group (2 arms). Primary endpoint: Pruritus score at 12 weeks. Status: unknown.
02
Drugs
thalidomide
03
Conditions
uremic pruritus
Beyond the preview
Go deeper on NCT05525234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05525234.